NewAmsterdam Pharma Company
Update in progressNAMS (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company focused on therapies for cardiometabolic diseases. It is developing Obicetrapib, an oral low-dose CETP inhibitor, in multiple trials as a standalone therapy and in combination with ezetimibe to lower LDL-C for cardiovascular disease. Obicetrapib is also in Phase 2a testing for Alzheimer’s disease. The company is headquartered in Naarden, Netherlands.
Company score
- Sentiment
- 0.23
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.16
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.15
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!